Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM

29 August 2025 (16:15 - 17:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Professor Michael Miller

Corporal Michael J. Crescenz VA Medical Center, Philadelphia (United States of America)

7 More presentations in this session

Presentation thumbnail

The association between the response of lipid-lowering agents and monogenic variants of familiar hypercholesteremia in Taiwan

Professor P. Liu (Tainan, TW)

Abstract Slides Video

Presentation thumbnail

Prospective validation of a self-report-based model for coronary artery calcium screening and assessment of treatment gaps in lipid-lowering therapy.

Doctor E. Hagberg (Gothenburg, SE)

Abstract Slides Video

Presentation thumbnail

BW-00112 targeting ANGPTL3 results in prolonged reductions in plasma triglycerides, LDL-C, and remnant-C in Chinese healthy subjects

Ms Y. Li (Shanghai, CN)

Abstract Slides Video

Presentation thumbnail

PCSK-9-inhibitor therapy improves endothelial function in patients with coronary artery disease

Doctor A. Bosch (Erlangen, DE)

Abstract Slides Video

Presentation thumbnail

Effectiveness of statins for primary prevention in the elderly - a propensity score matched cohort study

Doctor D. Leibowitz (Jerusalem, IL)

Abstract Slides Video

Access the full session

Session thumbnail

Drug therapy (1)

The Event

Event poster

ESC Congress 2025

29 August 2025 16:15 CET

You may be interested in

Congress Presentation

Icosapent ethyl reduces cardiovascular risk across apolipoprotein b and fasting triglyceride rich lipoprotein levels

Congress Presentation

Icosapent ethyl by baseline small dense low-density lipoprotein cholesterol: an analysis of REDUCE-IT

Congress Presentation

Effects of icosapent ethyl on risk and duration of hospitalizations and death in REDUCE-IT

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources